Group 1 - The core viewpoint of the articles highlights the performance and valuation of Dongxing Medical, which closed at 27.5 yuan with a PE ratio of 30.75 times, significantly lower than the industry average of 56.58 times [1][2] - Dongxing Medical's total market capitalization is 2.755 billion yuan, ranking 59th in the medical device industry based on PE ratio [1][2] - The company reported a revenue of 78.1865 million yuan for Q1 2025, reflecting a year-on-year decline of 14.84%, and a net profit of 12.064 million yuan, down 39.35% year-on-year, with a gross margin of 44.40% [1] Group 2 - The average PE ratio for the medical device industry is 56.58 times, with a median of 39.97 times, indicating that Dongxing Medical is undervalued compared to its peers [2] - The company specializes in the research, production, and sales of surgical medical devices, including products like endoscopic staplers and electric hydraulic surgical tables [1] - As of July 31, 2025, Dongxing Medical had 11,138 shareholders, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1]

Group 1 - The core viewpoint of the news is that Dongxing Medical's stock performance shows a decline in earnings and a low valuation compared to its industry peers, indicating potential investment concerns [1][2]. - Dongxing Medical's closing price on August 11 was 28.2 yuan, with a PE ratio of 31.53, marking a new low in 52 days and a total market capitalization of 2.825 billion yuan [1]. - The average PE ratio for the medical device industry is 56.56, with a median of 39.76, positioning Dongxing Medical at the 62nd rank within the industry [1]. Group 2 - As of July 31, 2025, Dongxing Medical has 11,138 shareholders, a decrease of 7 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1]. - The main business of Jiangsu Dongxing Smart Medical Technology Co., Ltd. includes the research, production, and sales of surgical medical devices, with key products such as endoscopic staplers and electric hydraulic surgical tables [1]. - The latest quarterly report for Q1 2025 shows Dongxing Medical achieved revenue of 78.1865 million yuan, a year-on-year decrease of 14.84%, and a net profit of 12.064 million yuan, down 39.35%, with a gross profit margin of 44.40% [1].

证券日报网讯东星医疗（301290）8月4日在互动平台回答投资者提问时表示，二级市场股价运行受市场 环境、投资偏好以及短期投机等多重复杂因素影响，公司始终坚持立足主业，聚焦市场需求，同时公司 管理层勤勉尽责，致力于持续提升经营业绩，持续创新，驱动公司内在价值增长。 ...

证券日报网讯东星医疗（301290）8月4日在互动平台回答投资者提问时表示，截至2025年7月31日，公 司股东总数为11138户(含信用账户)。 ...

Company Overview - Dongxing Medical closed at 26.88 yuan, up 1.28%, with a rolling PE ratio of 30.05, marking a new low in 39 days, and a total market capitalization of 2.693 billion yuan [1] - The company ranks 58th in the medical device industry, which has an average PE ratio of 55.41 and a median of 37.94 [1] Shareholder Information - As of July 18, 2025, Dongxing Medical had 11,145 shareholders, a decrease of 347 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Operations - Dongxing Medical specializes in the research, production, and sales of surgical medical devices, with key products including laparoscopic staplers, open staplers, stapler components, electric hydraulic surgical tables, shadowless surgical lights, and delivery beds [1] Financial Performance - In the first quarter of 2025, the company reported revenue of 78.1865 million yuan, a year-on-year decrease of 14.84%, and a net profit of 12.064 million yuan, down 39.35%, with a gross margin of 44.40% [1] Industry Comparison - The PE ratios for Dongxing Medical and its peers are as follows: Dongxing Medical at 30.05, with the industry average at 55.41 and the median at 37.94 [2]

Company Overview - Dongxing Medical closed at 26.2 yuan on July 16, with a 2.34% increase, and a rolling PE ratio of 29.29, marking a new low in 27 days, with a total market value of 2.625 billion yuan [1] - The company's main business includes the research, production, and sales of surgical medical devices, with key products such as endoscopic staplers, open staplers, stapler components, electric hydraulic surgical tables, shadowless surgical lights, and delivery beds [1] Financial Performance - In the latest quarterly report for Q1 2025, Dongxing Medical reported operating revenue of 78.1865 million yuan, a year-on-year decrease of 14.84%, and a net profit of 12.064 million yuan, down 39.35%, with a gross profit margin of 44.40% [1] Industry Comparison - The average PE ratio for the medical device industry is 51.87, with a median of 37.48, placing Dongxing Medical at the 62nd position in the industry ranking [1] - The company's static PE ratio is 26.94, and its price-to-book ratio is 1.16 [2] - Other companies in the industry have varying PE ratios, with the highest being 19.04 for Antu Biology and the lowest at 10.85 for Jiuan Medical [2] Capital Flow - On July 16, Dongxing Medical experienced a net inflow of main funds amounting to 5.7309 million yuan, although it has seen a total outflow of 9.1392 million yuan over the past five days [1]

致：江苏东星智慧医疗科技股份有限公司 江苏东星智慧医疗科技股份有限公司（以下简称公司）2025 年第一次临时股 东大会（以下简称本次股东大会）采取现场表决与网络投票相结合的方式，现场会 议于 2025 年 7 月 10 日（星期四）下午 2:30 在江苏省常州市武进区长扬路 24-4 号 公司会议室召开。北京市天元律师事务所（以下简称本所）接受公司聘任，指派本 所律师参加本次股东大会会议，并根据《中华人民共和国公司法》《中华人民共和 国证券法》（以下简称《证券法》）《上市公司股东会规则》（以下简称《股东会 规则》）以及《江苏东星智慧医疗科技股份有限公司章程》（以下简称《公司章程》） 等有关规定，就本次股东大会的召集、召开程序、出席现场会议人员的资格、召集 人资格、会议表决程序及表决结果等事项出具本法律意见。 北京市天元律师事务所 关于江苏东星智慧医疗科技股份有限公司 2025 年第一次临时股东大会的法律意见 京天股字（2025）第 464 号 为出具本法律意见，本所律师审查了《江苏东星智慧医疗科技股份有限公司第 四届董事会第十一次会议决议公告》《江苏东星智慧医疗科技股份有限公司第四届 监事会第十次会议决议公告 ...

证券代码：301290 证券简称：东星医疗 公告编号：2025- 029 江苏东星智慧医疗科技股份有限公司 2025年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开的时间： （1）现场会议时间：2025年7月10日（星期四）下午2:30； （2）网络投票时间：通过深圳证券交易所交易系统投票的时间为2025年7月 10日上午9:15-9:25，9:30—11:30，下午13:00—15:00；通过深圳证券交易所互联 网投票系统投票的时间为2025年7月10日上午9:15至下午3:00的任意时间。 2、会议召开方式：本次股东大会采用现场投票与网络投票相结合的方式。 3、会议召开地点：江苏省常州市武进区长扬路24-4号公司会议室。 4、会议召集人：公司董事会。 5、会议主持人：公司董事长万世平先生。 6、本次股东大会的召集、召开符合有关法律、行政法规、部门规章、规范 性文件和公 ...

Group 1 - The National Health Commission of China has issued notifications prohibiting the use of "ileal-jejunal anastomosis" for the treatment of type 2 diabetes and "cervical deep lymphatic vessel/lymph node-venous anastomosis" for Alzheimer's disease treatment [2][3] - The cervical deep lymphatic vessel/lymph node-venous anastomosis is primarily used for treating stubborn lymphedema, but its application for Alzheimer's disease lacks clear indications and contraindications, as well as high-quality evidence supporting its safety and efficacy [2] - The ileal-jejunal anastomosis, used for restoring intestinal continuity, has been deemed to lack foundational theoretical support and high-quality evidence for its safety and efficacy in treating type 2 diabetes [3] Group 2 - The domestic anastomosis device market may be impacted by these prohibitions, with the top 10 manufacturers in China including Johnson & Johnson, Covidien, Frankmann, Yisi Medical, Tianchen Medical, Palt Medical, David Medical, Rich Surgical, Yintukang Medical, and Brolansense [3] - Relevant listed companies in this sector include Dongxing Medical and Tianchen Medical, which may face challenges due to the new regulations [3]

Group 1 - The core viewpoint of the articles highlights Dongxing Medical's current stock performance, with a closing price of 25.93 yuan, an increase of 1.89%, and a rolling PE ratio of 28.99, marking a new low in 18 days [1] - Dongxing Medical's total market capitalization is reported at 25.97 billion yuan, with the average PE ratio in the medical device industry at 51.42, and the median at 37.44, placing Dongxing Medical at the 65th position in the industry ranking [1][2] - As of June 30, 2025, Dongxing Medical has 11,381 shareholders, a decrease of 123 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] Group 2 - Dongxing Medical specializes in the research, production, and sales of surgical medical devices, with key products including endoscopic staplers, open staplers, stapler components, electric hydraulic surgical tables, shadowless surgical lights, and delivery beds [1] - The latest quarterly report for Q1 2025 shows Dongxing Medical achieved operating revenue of 78.19 million yuan, a year-on-year decrease of 14.84%, and a net profit of 12.06 million yuan, down 39.35%, with a gross profit margin of 44.40% [1]